Bladder carcinoma data with clinical risk factors and molecular markers: A cluster analysis

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Redondo Gonzalez, Enrique ^a   De Castro, Leandro Nunes ^b   Moreno Sierra, Jesús ^a   Maestro De Las Casas, María Luisa ^a   Vera Gonzalez, Vicente ^c   Ferrari, Daniel Gomes ^b   Corchado, Juan Manuel ^d  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b MACKENZIE PRESBYTERIAN UNIVERSITY   (Brazil)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MOLECULAR MARKER; PROTEIN P53; TUMOR MARKER; TUMOR PROTEIN;

ANAMNESIS; ARTICLE; BLADDER CARCINOMA; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; FOLLOW UP; HIGH RISK POPULATION; HUMAN; OCCUPATIONAL EXPOSURE; OVERALL SURVIVAL; PHYSICAL EXAMINATION; PREOPERATIVE PERIOD; SMOKING; TRANSURETHRAL RESECTION; TUMOR VOLUME; URINE CYTOLOGY; BLADDER TUMOR; DISEASE FREE SURVIVAL; FACTUAL DATABASE; FEMALE; GENETICS; MALE; METABOLISM; MORTALITY; PATHOLOGY; RISK FACTOR; SURVIVAL RATE;

BIOMARKERS, TUMOR; DATABASES, FACTUAL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; NEOPLASM PROTEINS; RISK FACTORS; SURVIVAL RATE; URINARY BLADDER NEOPLASMS;

EID: 84926442223     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/168682     Document Type: Article

References (76)

1. M. Colombel, M. Soloway, H. Akaza et al., "Epidemiology, staging, grading, and risk stratification of bladder cancer," European Urology, Supplements, vol. 7, no. 10, pp. 618-626, 2008.
2. M. Brausi, J. A. Witjes, D. Lamm et al., "A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the international bladder cancer group," The Journal of Urology, vol. 186, no. 6, pp. 2158-2167, 2011.
3. M. Burger, J. W. F. Catto, G. Dalbagni et al., "Epidemiology and risk factors of urothelial bladder cancer," European Urology, vol. 63, no. 2, pp. 234-241, 2013.
4. S. L. Parker, T. Tong, S. Bolden, and P. A. Wingo, "Cancer statistics, 1996," CA: A Cancer Journal for Clinicians, vol. 46, no. 1, pp. 5-27, 1996.
5. J. P. Stein, G. D. Grossfeld, D. A. Ginsberg et al., "Prognostic markers in bladder cancer: a contemporary review of the literature," Journal of Urology, vol. 160, no. 3, pp. 645-659, 1998.
6. H. W. Herr, "Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome," The Journal of Urology, vol. 163, no. 1, pp. 60-62, 2000.
7. M. F. Botteman, C. L. Pashos, A. Redaelli, B. Laskin, and R. Hauser, "The health economics of bladder cancer: a comprehensive review of the published literature," PharmacoEconomics, vol. 21, no. 18, pp. 1315-1330, 2003.
8. R. J. Sylvester, A. P. van der Meijden, W. Oosterlinck et al., "Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials," European Urology, vol. 49, no. 3, pp. 466-477, 2006.
9. J. Moreno Sierra, M. L. Maestro de Las Casas, E. Redondo González et al., "Epidermal growth factor receptor (EGFR) in the prognosis of bladder carcinoma. Experience of 5 years," Archivos Espanoles de Urologia, vol. 53, no. 4, pp. 323-331, 2000.
10. J. M. Sierra, M. L. M. de las Casas, M. D. O. Heredia et al., "Nuevo método cuantitativo para determinar laproteina P53 en carcinomas vesicales," Archivos Espanoles de Urologia, vol. 50, no. 4, pp. 347-353, 1997.
11. J. Moreno Sierra, M. L. Maestro de las Casas, E. Redondo Gonzalez et al., "P185 (Neu) oncoprotein in the prognosis of bladder carcinoma. Experience of 5 years," Archivos Españoles de Urologí a, vol. 53, pp. 238-244, 2000.
12. J. Moreno Sierra, M. L. M. de las Casas, C. F. Pérez et al., "Quantification of p53 oncoprotein in bladder carcinoma: 5-year experience," Archivos Espanoles de Urologia, vol. 52, no. 3, pp. 220-227, 1999.
13. J. M. Sierra, M. M. de las Casas, M. D. O. Heredia, J. H. Gutiérrez, and L. R. Estevez, "Quantitative determination of epidermal growth factor urothelial receptor (EGFR) in superficial and invasive bladder carcinoma," Actas Urologicas Espanolas, vol. 18, no. 3, pp. 215-220, 1994.
14. M. A. Brausi, "Primary prevention and early detection of bladder cancer: two main goals for urologists," European Urology, vol. 63, no. 2, pp. 242-243, 2013.
15. J. Ferlay, H. Shin, F. Bray, D. Forman, C. Mathers, and D. Parkin, GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10, International Agency for Research on Cancer, Lyon, France, 2010.
16. C. Bosetti, P. Bertuccio, L. Chatenoud, E. Negri, C. la Vecchia, and F. Levi, "Trends in mortality from urologic cancers in Europe, 1970-2008," European Urology, vol. 60, no. 1, pp. 1-15, 2011.
17. J. Ferlay, G. Randi, C. Bosetti et al., "Declining mortality from bladder cancer in Europe," BJU International, vol. 101, no. 1, pp. 11-19, 2008.
18. N. D. Freedman, D. T. Silverman, A. R. Hollenbeck, A. Schatzkin, and C. C. Abnet, "Association between smoking and risk of bladder cancer among men and women," Journal of the American Medical Association, vol. 306, no. 7, pp. 737-745, 2011.
19. Z. Kirkali, T. Chan, M. Manoharan et al., "Bladder cancer: epidemiology, staging and grading, and diagnosis," Urology, vol. 66, no. 6, pp. 4-34, 2005.
20. D. T. Silverman, S. S. Devesa, L. E. Moore, and N. Rothman, "Bladder cancer," in Cancer Epidemiology and Prevention, D. Schottenfeld and J. F. Fraumeni, Eds., pp. 1101-1128, Oxford University Press, New York, NY, USA, 3rd edition, 2006.
21. C. M. Samanic, M. Kogevinas, D. T. Silverman et al., "Occupation and bladder cancer in a hospital-based case-control study in Spain," Occupational and Environmental Medicine, vol. 65, no. 5, pp. 347-353, 2008.
22. L. Rushton, S. Bagga, R. Bevan et al., "Occupation and cancer in Britain," British Journal of Cancer, vol. 102, no. 9, pp. 1428-1437, 2010.
23. S. Koutros, D. T. Silverman, D. Baris et al., "Hair dye use and risk of bladder cancer in the New England bladder cancer study," International Journal of Cancer, vol. 129, no. 12, pp. 2894-2904, 2011.
24. M. M. Ros, M. Gago-Dominguez, K. K. H. Aben et al., "Personal hair dye use and the risk of bladder cancer: a case-control study from The Netherlands," Cancer Causes & Control, vol. 23, no. 7, pp. 1139-1148, 2012.
25. T. Rafnar, S. H. Vermeulen, P. Sulem et al., "European genomewide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene," Human Molecular Genetics, vol. 20, no. 21, pp. 4268-4281, 2011.
26. M. K. B. Parmar, L. S. Freedman, T. B. Hargreave, and D. A. Tolley, "Prognostic factors for recurrence and follow-up policies in the treatment of superficial bladder cancer: report from the British Medical Research Council subgroup on superficial bladder cancer (urological cancer working party)," Journal of Urology, vol. 142, no. 2, pp. 284-288, 1989.
27. T. Shinka, A. Hirano, Y. Uekado, and T. Ohkawa, "Clinical study of prognostic factors of superficial bladder cancer treated with intravesical Bacillus Calmette-Guerin," British Journal of Urology, vol. 66, no. 1, pp. 35-39, 1990.
28. L. A. L. M. Kiemeney, J. A. Witjes, R. P. Heijbroek, F. M. J. Debruyne, and A. L. M. Verbeek, "Dysplasia in normal-looking urothelium increases the risk of tumour progression in primary superficial bladder cancer," European Journal of Cancer Part A: General Topics, vol. 30, no. 11, pp. 1621-1625, 1994.
29. K. H. Kurth, L. Denis, R. Sylvester, F. M. J. Debruyne, M. Pavone-Macaluso, and W. Oosterlinck, "Factors affecting recurrence and progression in superficial bladder tumours," European Journal of Cancer Part A: General Topics, vol. 31, no. 11, pp. 1840-1846, 1995.
30. F. Millán-Rodríguez, G. Chéchile-Toniolo, J. Salvador-Bayarri, J. Palou, and J. Vicente-Rodríguez, "Multivariate analysis of the prognostic factors of primary superficial bladder cancer," Journal of Urology, vol. 163, no. 1, pp. 73-78, 2000.
31. M. S. Soloway, M. Sofer, and A. Vaidya, "Contemporary management of stage T1 transitional cell carcinoma of the bladder," Journal of Urology, vol. 167, no. 4, pp. 1573-1583, 2002.
32. H. Miyamoto, J. S. Miller, D. A. Fajardo, T. K. Lee, G. J. Netto, and J. I. Epstein, "Non-invasive papillary urothelial neoplasms: the 2004 WHO/ISUP classification system," Pathology International, vol. 60, no. 1, pp. 1-8, 2010.
33. H. Miyamoto, F. Brimo, L. Schultz et al., "Low-grade papillary urothelial carcinoma of the urinary bladder: a clinicopathologic analysis of a post-world Health Organization/International Society of Urological Pathology classification cohort from a single academic center," Archives of Pathology and Laboratory Medicine, vol. 134, no. 8, pp. 1160-1163, 2010.
34. X.-R. Wu, "Urothelial tumorigenesis: a tale of divergent pathways," Nature Reviews Cancer, vol. 5, no. 9, pp. 713-725, 2005.
35. A. P. Mitra, R. H. Datar, and R. J. Cote, "Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification," Journal of Clinical Oncology, vol. 24, no. 35, pp. 5552-5564, 2006.
36. Y. Fradet, "Prognostic factors. Back to the future," in Superficial Bladder Cancer, W. R. Fair and F. Pagano, Eds., pp. 57-70, CRC Press, New York, NY, USA, 1997.
37. P. Rischmann, H. Bittard, D. Chopin et al., "AFU recommendations 1998. 'Committee on Cancer of the French Association of Urology'," Progres en Urologie, vol. 12, no. 5, pp. 1159-1160, 2002.
38. F. Millán-Rodríguez, G. Chéchile-Toniolo, J. Salvador-Bayarri, J. Palou, F. Algaba, and J. Vicente-Rodríguez, "Primary superficial bladder cancer risk groups according to progression, mortality and recurrence," The Journal of Urology, vol. 164, no. 3, pp. 680-684, 2000.
39. B. W. G. van Rhijn, T. C. M. Zuiverloon, A. N. Vis et al., "Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer," European Urology, vol. 58, no. 3, pp. 433-441, 2010.
40. J. Fernandez-Gomez, R. Madero, E. Solsona et al., "The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables," European Urology, vol. 60, no. 3, pp. 423-430, 2011.
41. P. R. Srinivas, S. Srivastava, S. Hanash, and J. Wright G.L., "Proteomics in early detection of cancer," Clinical Chemistry, vol. 47, no. 10, pp. 1901-1911, 2001.
42. G. J. Netto, "Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet?" Nature Reviews Urology, vol. 9, no. 1, pp. 41-51, 2012.
43. R. Røtterud, J. M. Nesland, A. Berner, and S. D. Fosså, "Expression of the epidermal growth factor receptor family in normal and malignant urothelium," BJU International, vol. 95, no. 9, pp. 1344-1350, 2005.
44. S. Simonetti, R. Russo, G. Ciancia, V. Altieri, G. de Rosa, and L. Insabato, "Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and FISH analysis of c-erbB-2 gene and chromosome 17," International Journal of Surgical Pathology, vol. 17, no. 3, pp. 198-205, 2009.
45. D. E. Neal, R. R. Hall, C. Marsh, P. D. Abel, J. R. C. Sainsbury, and A. L. Harris, "Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours," The Lancet, vol. 1, no. 8425, pp. 366-368, 1985.
46. D. E. Neal, L. Sharples, K. Smith, J. Fennelly, R. R. Hall, and A. L. Harris, "The epidermal growth factor receptor and the prognosis of bladder cancer," Cancer, vol. 65, no. 7, pp. 1619-1625, 1990.
47. A. J. Colquhoun and J. K. Mellon, "Epidermal growth factor receptor and bladder cancer," Postgraduate Medical Journal, vol. 78, no. 924, pp. 584-589, 2002.
48. K. Mellon, C. Wright, P. Kelly, C. H. Horne, and D. E. Neal, "Long-term outcome related to epidermal growth factor receptor status in bladder cancer," The Journal of Urology, vol. 153, pp. 919-925, 1995.
49. J. E. Nutt, J. K. Mellon, K. Qureshi, and J. Lunec, "Matrix metalloproteinase-1 is induced by epidermal growth factor in human bladder tumour cell lines and is detectable in urine of patients with bladder tumours," British Journal of Cancer, vol. 78, no. 2, pp. 215-220, 1998.
50. B. D. Kavanagh, P.-S. Lin, P. Chen, and R. K. SchmidtUllrich, "Radiation-induced enhanced proliferation of human squamous cancer cells in vitro: a release from inhibition by epidermal growth factor," Clinical Cancer Research, vol. 1, no. 12, pp. 1557-1562, 1995.
51. H. Roh, J. Pippin, and J. A. Drebin, "Down-regulation of HER2/neu expression induces apoptosis in human cancer cells that overexpress HER2/neu," Cancer Research, vol. 60, no. 3, pp. 560-565, 2000.
52. R. Gandour-Edwards, P. N. Lara Jr., A. K. Folkins et al., "Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?" Cancer, vol. 95, no. 5, pp. 1009-1015, 2002.
53. Z. Latif, A. D. Watters, I. Dunn, K. Grigor, M. A. Underwood, and J. M. S. Bartlett, "HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy?" European Journal of Cancer, vol. 40, no. 1, pp. 56-63, 2004.
54. S. Eissa, H. S. Ali, A. H. Al Tonsi, A. Zaglol, and O. El Ahmady, "HER2/neu expression in bladder cancer: relationship to cell cycle kinetics," Clinical Biochemistry, vol. 38, no. 2, pp. 142-148, 2005.
55. C. Bolenz, S. F. Shariat, P. I. Karakiewicz et al., "Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder," BJU International, vol. 106, no. 8, pp. 1216-1222, 2010.
56. S. Krüger, G. Weitsch, H. Büttner et al., "Overexpression of cerbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome," International Journal of Oncology, vol. 21, no. 5, pp. 981-987, 2002.
57. V. Ravery, D. Grignon, J. Angulo et al., "Evaluation of epidermal growth factor receptor, transforming growth factor alpha, epidermal growth factor and c-erbB2 in the progression in invasive bladder cancer," Urological Research, vol. 25, no. 1, pp. 9-17, 1997.
58. R. E. Jimenez, M. Hussain, F. J. Bianco Jr. et al., "Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors," Clinical Cancer Research, vol. 7, no. 8, pp. 2440-2447, 2001.
59. A. Chakravarti, K. Winter, C.-L. Wu et al., "Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group," International Journal of Radiation Oncology Biology Physics, vol. 62, no. 2, pp. 309-317, 2005.
60. C. Bolenz and Y. Lotan, "Translational research in bladder cancer: from molecular pathogenesis to useful tissue biomarkers," Cancer Biology and Therapy, vol. 10, no. 5, pp. 407-415, 2010.
61. P. C. H. Chen, H. J. Yu, Y. H. Chang, and C. C. Pan, "Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression," Journal of Clinical Pathology, vol. 66, no. 2, pp. 113-119, 2013.
62. T. H. Ecke, H. H. Schlechte, G. Schulze, S. V. Lenk, and S. A. Loening, "Four tumour markers for urinary bladder cancer-tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation," Anticancer Research, vol. 25, no. 1, pp. 635-641, 2005.
63. C. A. Finlay, P. W. Hinds, T. H. Tan, D. Eliyahu, M. Oren, and A. J. Levine, "Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life," Molecular and Cellular Biology, vol. 8, no. 2, pp. 531-539, 1988.
64. B. George, R. H. Datar, L. Wu et al., "p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer," Journal of Clinical Oncology, vol. 25, no. 34, pp. 5352-5358, 2007.
65. Z. Popov, A. Hoznek, M. Colombel et al., "The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder," Cancer, vol. 80, no. 8, pp. 1472-1481, 1997.
66. A. S. Sarkis, G. Dalbagni, C. Cordon-Cardo et al., "Nuclear over-expression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression," Journal of the National Cancer Institute, vol. 85, no. 1, pp. 53-59, 1993.
67. A. S. Sarkis, G. Dalbagni, C. Cordon-Cardo et al., "Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder," Journal of Urology, vol. 152, no. 2, pp. 388-392, 1994.
68. S. F. Shariat, C. Bolenz, P.I. Karakiewiczetal., "P53 expression in patients with advanced urothelial cancer of the urinary bladder," BJU International, vol. 105, no. 4, pp. 489-495, 2010.
69. S. Saidi, Z. Popov, S. Stavridis, V. Janevska, and S. Panov, "Digital quantitative immunofluorescent detection of p53 protein in urinary bladder cancer tissue samples," Prilozi, vol. 34, pp. 167-175, 2013.
70. F. K. Mostofi, C. J. J. Davis, and I. A. Sesterhenn, Histological Typing of Urinary Bladder Tumours, WHO(World HealthOrganization) International Histological Classification of Tumours, Springer, Berlin, Germany, 1999.
71. L. H. Sobin and C. Wittekind, TNM: Classification of Malignant Tumours, Wiley-Liss, 5th edition, 1997.
72. A. K. Jain, M. N. Murty, and P. J. Flynn, "Data clustering: a review," ACM Computing Surveys (CSUR), vol. 31, no. 3, pp. 264-323, 1999.
73. L. Kaufman and P. J. Rousseeuw, Finding Groups in Data: An Introduction to Cluster Analysis, Wiley-Interscience, New York, NY, USA, 2005.
74. B. S. Everitt, S. Landau, and M. Leese, Cluster Analysis, John Wiley & Sons, New York, NY, USA, 2009.
75. D. Pyle, Data Preparation for Data Mining (The Morgan Kaufmann Series in Data Management Systems), Morgan Kaufmann, Boston, Mass, USA, 1999.
76. S. Zhang, C. Zhang, and Q. Yang, "Data preparation for data mining," Applied Artificial Intelligence, vol. 17, no. 5-6, pp. 375-381, 2003.